6266 related articles for article (PubMed ID: 3698058)
1. Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine.
Fidler IJ
Cancer Immunol Immunother; 1986; 21(3):169-73. PubMed ID: 3698058
[TBL] [Abstract][Full Text] [Related]
2. Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide.
Saiki I; Milas L; Hunter N; Fidler IJ
Cancer Res; 1986 Oct; 46(10):4966-70. PubMed ID: 3756858
[TBL] [Abstract][Full Text] [Related]
3. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
Fidler IJ; Fogler WE; Brownbill AF; Schumann G
J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
[TBL] [Abstract][Full Text] [Related]
4. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma.
Fidler IJ; Fan D; Ichinose Y
Invasion Metastasis; 1989; 9(2):75-88. PubMed ID: 2496047
[TBL] [Abstract][Full Text] [Related]
5. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide.
Key ME; Talmadge JE; Fogler WE; Bucana C; Fidler IJ
J Natl Cancer Inst; 1982 Nov; 69(5):1198-98. PubMed ID: 6957661
[TBL] [Abstract][Full Text] [Related]
6. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin.
Hisano G; Fidler IJ
Cancer Immunol Immunother; 1982; 14(2):61-6. PubMed ID: 6965228
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
[TBL] [Abstract][Full Text] [Related]
8. Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases.
Schroit AJ; Fidler IJ
Prog Clin Biol Res; 1982; 102 pt A():347-55. PubMed ID: 7167445
[No Abstract] [Full Text] [Related]
9. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
10. Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide.
Koff WC; Showalter SD; Hampar B; Fidler IJ
Science; 1985 Apr; 228(4698):495-7. PubMed ID: 2984772
[TBL] [Abstract][Full Text] [Related]
11. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.
Sone S; Utsugi T; Tandon P; Ogawara M
Cancer Immunol Immunother; 1986; 22(3):191-6. PubMed ID: 3731204
[TBL] [Abstract][Full Text] [Related]
12. Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.
Fogler WE; Wade R; Brundish DE; Fidler IJ
J Immunol; 1985 Aug; 135(2):1372-7. PubMed ID: 4008926
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
[TBL] [Abstract][Full Text] [Related]
14. Prevention of chemotherapy- or X-irradiation-induced monocytopenia by oral administration of lipophilic muramyl tripeptide.
Killion JJ; Brown DR; Wilson MR; Lloyd MM; Fidler IJ
Oncol Res; 1994; 6(8):357-64. PubMed ID: 7894085
[TBL] [Abstract][Full Text] [Related]
15. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P
J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
[TBL] [Abstract][Full Text] [Related]
17. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice.
Dinney CP; Tanguay S; Bucana CD; Eve BY; Fidler IJ
J Interferon Cytokine Res; 1995 Jun; 15(6):585-92. PubMed ID: 7553228
[TBL] [Abstract][Full Text] [Related]
18. Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) promotes haemopoietic recovery in irradiated mouse.
Fedorocko P
Int J Radiat Biol; 1994 Apr; 65(4):465-75. PubMed ID: 7908934
[TBL] [Abstract][Full Text] [Related]
19. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.
Gianan MA; Kleinerman ES
Cancer Biother Radiopharm; 1998 Oct; 13(5):363-8. PubMed ID: 10851426
[TBL] [Abstract][Full Text] [Related]
20. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
Tandon P; Utsugi T; Sone S
Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
